# Harbour BioMed Receives China NMPA Approval of Batoclimab Injection (Subcutaneous Injection) for the Treatment of Generalized Myasthenia Gravis

- Source: PR Newswire
- Published: 2026-10-23T00:02:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/harbour-biomed-receives-china-nmpa-approval-of-batoclimab-injection-subcutaneous-injection-for-the-treatment-of-generalized-myasthenia-gravis-302917545.html
- Canonical: https://groundlevelnews.com/story/harbour-biomed-receives-china-nmpa-approval-of-batoclimab-injection-su-8a251d/

The first NMPA-approved anti-FcRn therapy to complete its full clinical development for gMG patients in China CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Oct. 22, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire._